Supha Pharmachem 2025: ₹100 crore raise, committee revamp

Key developments at a glance

Remedium Lifecare Limited has gone through a cluster of corporate actions and disclosures across 2024-25, including a name change, capital-related proposals, and board and committee changes. The company has informed exchanges about Board meetings tied to results, fundraising options and governance actions under SEBI’s LODR framework. Separately, shareholder approvals were recorded for changes in authorised share capital through an AGM and a postal ballot process. The company also disclosed the conduct of an AGM through video conferencing or other audio-visual means (VC/OAVM), via a newspaper publication.

A separate operational notice included in the material asked clients to note a change in “PAY IN” for a BSE account (CDSL A/c No. 1201250000000691) and advised NSDL account holders to use an inter-depository slip. The notice shared a contact number for assistance.

MCA approval for the new company name

The company disclosed that the Ministry of Corporate Affairs (MCA) approved its change of name through a certificate of incorporation effective 15/12/2025. The name changed from Remedium Lifecare Ltd. to Supha Pharmachem Limited. This was positioned as a regulatory milestone following earlier board-level proposals around a name change.

In earlier disclosures, the board had approved a proposal to change the name to “SUPRA PHARMACHEM LIMITED” or any other name as approved by the Registrar of Companies (ROC), subject to shareholder and regulatory approvals. The eventual approved name, as disclosed, became Supha Pharmachem Limited. For investors, the naming sequence matters because exchange disclosures and corporate records can show both the former and new names during the transition period.

Share capital changes approved by shareholders

The material notes that at the company’s 35th Annual General Meeting held on 26 June 2024, members approved an increase in authorised share capital. The authorised share capital was increased from ₹30 crore (30,00,00,000 equity shares of Re 1 each) to ₹42 crore (42,00,00,000 equity shares of Re 1 each).

It also states that members, on 24 August 2024, approved a resolution through a postal ballot process to alter the authorised share capital from the existing ₹42 crore. The text provided does not include the new authorised capital figure after this postal ballot item, so the post-alteration number cannot be stated from the available material.

Board approvals: higher authorised capital and fundraising plan

In the later set of disclosures, the Board approved an increase in authorised share capital from ₹110 crore to ₹210 crore. Alongside this, the Board approved raising up to ₹100 crore through equity shares, convertible instruments, rights issue, or other permissible securities, in one or more tranches, subject to regulatory approvals.

Another line item in the source states that Remedium Lifecare approved fundraising “not exceeding 1 billion rupees”, which is ₹100 crore, aligning with the fundraising limit described elsewhere. The Board meeting outcome referenced approvals around (1) change of name, (2) increase in authorised share capital and (3) a proposal for further capital raising.

Rights issue trail: ratio and offer documents

The disclosures include a set of Board meeting items connected to a rights issue process. The company considered and approved the terms of the rights issue, including the ratio of 61 rights equity shares for every 50 fully paid equity shares held by eligible shareholders on the record date.

Separately, it disclosed approval of the Letter of Offer and related documents for a proposed rights issue of 491,904,000 equity shares of Re 1 each, aggregating to 4,919.04 lakh equity shares (face value basis). Converting the value stated in lakhs, 4,919.04 lakh equals ₹49.1904 crore on a face value basis at Re 1 per share. The material does not provide the issue price, so the total funds to be raised via this rights issue cannot be computed from the provided text.

AGM-related newspaper publication and VC/OAVM mode

An exchange item dated 26 August 2025 refers to “Submission of newspaper publication intimating members for holding ensuing AGM for 2024-25 through VC/OAVM”. This indicates the company used newspaper publication as a communication route to inform shareholders about the AGM process and the virtual mode.

Separately, a narrative note states that on 2 October 2025, the company concluded its 36th AGM and a Board meeting in Mumbai. At the AGM, shareholders approved adoption of the audited standalone and consolidated financial statements for FY25, and approved the re-election of Mr. Mansoor Vahab as Non-executive Director retiring by rotation.

Board and committee changes under SEBI LODR

The disclosures include committee reconstitution and board changes reported under Regulation 30. The Board, at a meeting held on 31 October 2025, approved reconstitution of committees due to changes in board members. The composition was disclosed in detail:

• Audit Committee (Regulation 18): Mr. Vijay Pal Singh Gulya (Independent Director) as Chairman (w.e.f. 31 Oct 2025); Mrs. Shamim Adil Michal (Independent Director, appointed 22 Jan 2025) and Mr. Rambhajan Vishwakarma (Non-Executive, Non-Independent Director) as members.
• Nomination and Remuneration Committee (Regulation 19): Mrs. Shamim Adil Michal as Chairperson; Mr. Vijay Pal Singh Gulya and Mr. Rambhajan Vishwakarma as members.
• Stakeholders’ Relationship Committee (Regulation 20): Mr. Rambhajan Vishwakarma as Chairman; Mrs. Shamim Adil Michal and Mr. Vijay Pal Singh Gulya as members.
• Risk Management Committee (Regulation 21): Mrs. Shamim Adil Michal as Chairperson; Mr. Adarsh Munjal (Executive Director) and Mr. Vijay Pal Singh Gulya as members.

The material also mentions the proposal to regularise the appointment of Mr. Rambhajan Vishwakarma (DIN: 11360922) as Non-Executive, Non-Independent Chairman of the Board.

Appointments, resignations, and a reported demise

The source includes references to appointments of Mr. Rambhajan Vishwakarma and Mr. Vignesh Laxman Gawde, as part of Board actions that also included a postal ballot notice and committee reconstitution. It also lists director resignations: Dipesh Vinod Vaidya (Non-Executive Independent Director) with effect from 6 October 2025, and Mansoor Abdul Vahab (Non-Executive Independent Director) effective 29 October 2025.

Another line item states: “Supha Pharmachem Limited Announces Demise of Kapil Goplani, Company Secretary and Compliance Officer.” The snippet does not provide full context or a year within the visible extract.

Summary table of disclosed facts

Why these disclosures matter for investors

For investors tracking the company, the combination of a name change, governance updates, and capital actions can affect how filings appear across platforms and how corporate actions are interpreted. The authorised share capital increases and fundraising approvals indicate the company has kept multiple financing routes open, including a rights issue and other permissible instruments, subject to approvals.

The committee reconstitution matters because it sets the oversight structure for audit, remuneration, stakeholder grievances, and risk management, and it reflects changes in the Board’s composition. Finally, the AGM disclosures and the use of VC/OAVM show the compliance steps taken to reach shareholders through formal communication channels.

What to watch next

Based on the items in the material, the next milestones typically remain tied to completion of shareholder approvals where required, regulatory clearances for capital actions, and exchange filings linked to results and corporate actions. Investors will also track subsequent disclosures for any finalised terms of fundraising instruments, including pricing and timelines, if and when they are announced.